Business Wire

International Energy Disputes Partner David Hesse Joins Hunton Andrews Kurth in London

22.8.2023 11:00:00 EEST | Business Wire | Press release

Share

David Hesse, an energy disputes attorney whose practice focuses on oil and gas litigation and arbitration matters with a strong emphasis on Africa has joined Hunton Andrews Kurth LLP as a partner in London.

Hesse advises states and national oil and gas companies on disputes, settlements, and upstream activities, as well as international tenders, refinery projects, farm-out agreements, and other contracts in the petroleum and petrochemical industries. His practice includes international commercial arbitration matters involving Anglophone and Francophone states and state entities in North, East, Central and West Africa.

Previously a partner with Clyde & Co., Hesse joins longtime colleague and collaborator Philip Mace as the newest additions to Hunton Andrews Kurth’s London-based energy team. Mace, who also recently joined the firm as a partner from Clyde & Co., is an experienced corporate lawyer whose practice is focused on energy and upstream oil and gas transactions.

“Robust global demand for large scale energy and infrastructure projects and the natural proliferation of disputes associated with those ventures continue to drive the need for a strong international arbitration and litigation practice,” said Tom Taylor, co-head of Hunton Andrews Kurth’s litigation team. “David is an outstanding lawyer whose experience and ability to navigate complex international disputes make him an ideal complement to the team.”

Hesse has extensive experience before international institutions including the International Chamber of Commerce (ICC) and International Centre for Settlement of Investment Disputes (ICSID). A selection of his notable representations prior to joining the firm include:

  • Advised the Government of Tanzania and the Tanzanian Electric Supply Company Limited (TANESCO) as co-lead international counsel with a local firm, in connection with related contract and treaty claims (ICSID) by Standard Chartered Bank.
  • Advised the Nigerian National Petroleum Corporation (NNPC) and supporting Nigerian counsel in connection with over $1 billion in claims by China National Offshore Oil Corporation (CNOOC) and South Atlantic Petroleum (SAPETRO) under a production sharing contract.
  • Advised the Government of Algeria and Sonatrach in connection with parallel proceedings (ICSID and UNCITRAL) by an oil and gas exploration company and an international shipping and logistics company for claims in excess of $8 billion relating to Algeria’s Windfall Profit Tax.
  • Advised the Government of Uganda and the Uganda Revenue Authority in connection with a $405 million claim by Heritage Oil (UNCITRAL) and a $473 million claim by Tullow Oil plc (ICSID) for recovery of capital gains tax under a production sharing agreement.
  • Advised ZCCM Investment Holdings PLC in connection with $2 billion in claims by Vedanta Resources Holdings Limited (UNCITRAL) relating to Konkola Copper Mines plc in Zambia.

“David’s practice complements our London-based projects and corporate offerings and reinforces our internationally recognized strength in the energy sector,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are excited to welcome David to the firm.”

A recognized lawyer in Chambers Global and Legal 500, Hesse is also an Honorary Lecturer at the Centre for Energy, Petroleum and Mineral Law and Policy at the University of Dundee and a lecturer at the CWC School for Energy. He is a regular speaker at international arbitration and energy conferences, including Juris Conference, GAR Energy Disputes, and GAR Live.

Hesse received his undergraduate degree from the University of Cincinnati, his LLB (Maîtres) from the Universitie de Paris – La Sorbonne, and his LLM from Columbia Law School.

Hunton Andrews Kurth’s international arbitration and transnational litigation practice represents clients around the globe. We regularly handle investor-state arbitrations before the International Centre for Settlement of Investment Disputes (ICSID), and commercial arbitrations before the International Court of Arbitration of the International Chamber of Commerce (ICC); the London Court of International Arbitration (LCIA); the Singapore International Arbitration Centre (SIAC); the Permanent Court of Arbitration in The Hague; and the American Arbitration Association (AAA) and its international division, the International Centre for Dispute Resolution (ICDR). We also work with clients in multi-jurisdictional matters, working closely with counsel in local forums.

About Hunton Andrews Kurth LLP

With over 900 lawyers in the United States, Asia, Europe and the Middle East, Hunton Andrews Kurth LLP is a global firm that serves clients across a broad range of complex transactional, litigation and regulatory matters. The firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable experience in more than 100 distinct areas of practice, including privacy and cybersecurity, intellectual property, environmental, and mergers and acquisitions.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

The PR Office
hak@theproffice.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye